Shorter EGFR Dinucleotide Repeat Length Predicts Better Response of Patients with Advanced Non-small Cell Lung Cancer to EGFR Tyrosine Kinase Inhibitor.
The purpose of this study is to evaluate the association between intron 1 CA-repeat polymorphisms of the epidermal growth factor receptor gene (EGFR) and the clinical outcome of Chinese patients with advanced non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). We genotyped the intron 1 CA-repeat genetic polymorphisms of EGFR in 84 Chinese patients with NSCLC. The relationship between the length of the CA repeats and EGFR mutations in exons 18-21 in the 84 patients was elucidated. We then analyzed the association between the length of the CA repeats and the clinical outcome of EGFR-TKI-treated patients with NSCLC. EGFR mutations in exon 19 were significantly associated with shorter CA repeats. Patients with shorter CA repeats had a significantly longer progression-free survival with EGFR-TKI treatment than those with longer CA repeats. Our results suggest that shorter CA repeats in intron 1 of EGFR are associated with EGFR mutations and the clinical outcomes of TKI-treated patients with NSCLC.
Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine Cancer Institute, Tongjing University, No 507 Zhengmin Road, Shanghai, 200433, People's Republic of China.
Bin
B
Chen
Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine Cancer Institute, Tongjing University, No 507 Zhengmin Road, Shanghai, 200433, People's Republic of China.
Jie
J
Luo
Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine Cancer Institute, Tongjing University, No 507 Zhengmin Road, Shanghai, 200433, People's Republic of China.
Weiqing
W
Gu
Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine Cancer Institute, Tongjing University, No 507 Zhengmin Road, Shanghai, 200433, People's Republic of China.
Li
L
Shen
Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine Cancer Institute, Tongjing University, No 507 Zhengmin Road, Shanghai, 200433, People's Republic of China. heyongwang2014@163.com.
Heyong
H
Wang
Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine Cancer Institute, Tongjing University, No 507 Zhengmin Road, Shanghai, 200433, People's Republic of China. drsongwenzhou2014@163.com.
Songwen
S
Zhou
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D018900:Dinucleotide Repeats; D066246:ErbB Receptors / Q000235:genetics*; D005091:Exons; D005260:Female; D006801:Humans; D007438:Introns; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011110:Polymorphism, Genetic; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors
Advanced non-small cell lung cancer; CA repeat; Epidermal growth factor receptor; Intron 1; Tyrosine kinase inhibitors